These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2092150

  • 1. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G, Giovagnoli MR, Vecchione A, Cosentino L, Benci F, Manna A, Marchei G, Vittori I, Frati L.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract] [Full Text] [Related]

  • 2. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
    Bumma C, Bramardi AM, Lauria G, Arese P, Marchetti G.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
    [No Abstract] [Full Text] [Related]

  • 3. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L, Onetto M, Gardin G, Costanzi B, Giudici S, Vitiello E, Merlini L, Naso C, Zannini C, Paganuzzi M.
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M, Hippeläinen M, Kettunen J, Salmela E, Penttilä I, Alhava E.
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [Abstract] [Full Text] [Related]

  • 5. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y, Martini MC, Pastorino G, Moraglio L, Vallauri M, Brondi P, Brema F.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
    Zanon C, Alluminio P, Margarita V, Sottimano C, Giuliani F, Neri G, Ballario F.
    Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
    [Abstract] [Full Text] [Related]

  • 12. [The existence of a correlation between the serum values of MCA and CA 15.3 in patients with digestive tumors].
    Roiz MC, Vizoso F, Allende MT, Ruibal A.
    Rev Clin Esp; 1990 Nov; 187(7):376. PubMed ID: 2091127
    [No Abstract] [Full Text] [Related]

  • 13. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T, Schürenkämper P, Minguillon C, Lichtenegger W.
    Anticancer Res; 1997 Nov; 17(4B):2953-4. PubMed ID: 9329573
    [Abstract] [Full Text] [Related]

  • 14. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W.
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract] [Full Text] [Related]

  • 15. MCA performance in preoperative breast cancer patients.
    Donadeo A, Micelli G, Quaranta M, Atlante A, Schittulli F.
    Anticancer Res; 1995 Nov; 15(2):527-9. PubMed ID: 7763034
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
    Priolo G, Pecchio F, Rapellino M, Aimo G, Spertino F, Pepe C.
    J Nucl Med Allied Sci; 1990 Nov; 34(4 Suppl):21-3. PubMed ID: 2092121
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.